Neurol. praxi. 2015;16(6):334-339

Central nervous system vasculitis

MUDr. Aleš Tomek, Ph.D., FESO
Neurologická klinika 2. LF UK a FN Motol, Praha

Vasculitides are a very heterogeneous group of diseases with a wide range of clinical presentations. Due to inflammatory changes in the vessel wall, distal tissue is jeopardized by ischaemia (vascular occlusion, embolization) or, less frequently, vessel rupture and bleeding can occur at the site of the injury. Clinically, three basic presentations of CNS vasculitis manifestations can be specified: acute territorial ischaemic stroke, i.e. involvement of large arteries with a typical presentation consistent with the territory affected, but often with accompanying atypical symptoms in the medical history (cephalalgia, encephalopathy, or epileptic seizures); "atypical multiple sclerosis (MS-plus)" with involvement of small arteries, having a relapsing-remitting course with atypical MS symptoms (epileptic seizures, headaches); and acute encephalopathy with progressive disturbance of consciousness. In CNS vasculitides, immunosuppressive therapy always has to be supplemented by antiplatelet or anticoagulant therapy. Vascular risks are to be managed aggressively (high-dose statins, antihypertensive drugs, diabetes control). The diagnosis of CNS vasculitis should be taken into consideration despite its very low incidence, given the options of targeted therapy with a good chance of improving the prognosis in affected patients.

Keywords: vasculitis, ischaemic stroke, primary CNS vasculitis

Published: December 16, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomek A. Central nervous system vasculitis. Neurol. praxi. 2015;16(6):334-339.
Download citation

References

  1. Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore). 1988; 67: 20-39. Go to original source... Go to PubMed...
  2. Daniels LB, Tjajadi MS, Walford HH, Jimenez-Fernandez S, Trofimenko V, Fick, Jr DB, Phan HA, Linz PE, Nayak K, Kahn AM, Burns JC, Gordon JB. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation 2012; 125: 2447-2453. Go to original source... Go to PubMed...
  3. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11. Go to original source... Go to PubMed...
  4. Koide K. Aortitis syndrome. Nihon Rinsho 1992; 50: 343-353. Go to original source...
  5. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993; 33: 4-9. Go to original source... Go to PubMed...
  6. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae S, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Sam Lim S, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks Jr. AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin Jr. G, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686. Go to original source... Go to PubMed...
  7. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Tatlisumak T. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke. The Helsinki Young Stroke Registry. Stroke 2009; 40: 1195-1203. Go to original source... Go to PubMed...
  8. Ringleb PA, Strittmatter EI, Loewer M, Hartmann M, Fiebach JB, Lichy C, Weber R, Jacobi C, Amendt K, Schwaninger M. Cerebrovascular manifestations of Takayasu arteritis in Europe. Rheumatology 2005; 44: 1012-1015. Go to original source...
  9. Salvarani C, Brown RD, Christianson T, Miller DV, Giannini C, Huston J III, Hunder GG. An Update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis. Medicine (Baltimore) 2015; 94: e738. Go to original source... Go to PubMed...
  10. Scolding NJ, Jayne DR, Zajicek JP, Meyer PAR, Wraight EP, Lockwood CM. The syndrome of cerebral vasculitis: recognition, diagnosis and management. Quarterly Journal of Medicine 1997; 90: 61-73. Go to original source...
  11. Torres J, Loomis C, Messe S. Yield and safety of brain biopsy in patients with suspected CNS vasculitis. Neurology 2015; 84: Supplement S30.003. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.